$-0.05 EPS Expected for Sangamo Therapeutics, Inc. (SGMO); Dxp Enterprises (DXPE) SI Decreased By 3.54%

April 17, 2018 - By Marguerite Chambers

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Analysts expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report $-0.05 EPS on May, 9.They anticipate $0.18 EPS change or 78.26% from last quarter’s $-0.23 EPS. After having $-0.15 EPS previously, Sangamo Therapeutics, Inc.’s analysts see -66.67% EPS growth. The stock increased 7.26% or $1.3 during the last trading session, reaching $19.2. About 1.29M shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 352.38% since April 17, 2017 and is uptrending. It has outperformed by 340.83% the S&P500.

Dxp Enterprises Inc (NASDAQ:DXPE) had a decrease of 3.54% in short interest. DXPE’s SI was 613,000 shares in April as released by FINRA. Its down 3.54% from 635,500 shares previously. With 304,100 avg volume, 2 days are for Dxp Enterprises Inc (NASDAQ:DXPE)’s short sellers to cover DXPE’s short positions. The SI to Dxp Enterprises Inc’s float is 3.89%. The stock increased 2.63% or $0.97 during the last trading session, reaching $38.06. About 55,012 shares traded. DXP Enterprises, Inc. (NASDAQ:DXPE) has risen 24.48% since April 17, 2017 and is uptrending. It has outperformed by 12.93% the S&P500.

Among 2 analysts covering DXP Enterprises (NASDAQ:DXPE), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. DXP Enterprises had 5 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by KeyBanc Capital Markets with “Sector Weight” on Friday, May 26. The firm has “Sector Weight” rating by KeyBanc Capital Markets given on Tuesday, July 21. Stephens maintained the stock with “Buy” rating in Wednesday, March 21 report. As per Monday, October 16, the company rating was maintained by KeyBanc Capital Markets. As per Friday, September 15, the company rating was maintained by KeyBanc Capital Markets.

DXP Enterprises, Inc. engages in distributing maintenance, repair, and operating products, equipment, and services to energy and industrial clients in the United States. The company has market cap of $660.74 million. It operates through three divisions: Service Centers, Supply Chain Services, and Innovative Pumping Solutions. It has a 41.11 P/E ratio. The Service Centers segment offers MRO products, equipment, and integrated services, including technical expertise and logistics services.

Investors sentiment decreased to 0.98 in Q4 2017. Its down 0.47, from 1.45 in 2017Q3. It fall, as 11 investors sold DXP Enterprises, Inc. shares while 38 reduced holdings. 13 funds opened positions while 35 raised stakes. 12.94 million shares or 0.89% more from 12.83 million shares in 2017Q3 were reported. California-based Assetmark Inc has invested 0% in DXP Enterprises, Inc. (NASDAQ:DXPE). State Street Corporation has 366,116 shares. Schwab Charles Investment Mngmt Incorporated reported 66,396 shares stake. Pinebridge Invests L P reported 25,592 shares or 0.02% of all its holdings. Goldman Sachs Gru holds 0% or 47,776 shares in its portfolio. Northern Trust stated it has 195,804 shares or 0% of all its holdings. 96,250 are owned by Alphaone Ser Ltd Liability Corporation. Barclays Public Limited owns 0% invested in DXP Enterprises, Inc. (NASDAQ:DXPE) for 2,499 shares. Pnc Grp stated it has 311 shares or 0% of all its holdings. Mason Street Advsr Lc invested in 0% or 4,116 shares. Metropolitan Life Ins Ny reported 5,378 shares. Aqr Cap Mgmt Ltd Liability owns 71,550 shares or 0% of their US portfolio. Moreover, Bancorporation Of Montreal Can has 0% invested in DXP Enterprises, Inc. (NASDAQ:DXPE) for 738 shares. Geode Management Ltd holds 0% or 130,569 shares. California Pub Employees Retirement System invested in 68,159 shares.

Since December 29, 2017, it had 0 insider purchases, and 6 selling transactions for $2.72 million activity. On Monday, March 26 the insider Jeffery John Jay sold $120,000. $74,200 worth of stock was sold by HAMLIN TODD on Friday, December 29. On Thursday, March 29 VINSON DAVID C sold $291,600 worth of DXP Enterprises, Inc. (NASDAQ:DXPE) or 7,290 shares. On Thursday, March 29 YEE KENT NEE HUNG sold $124,936 worth of DXP Enterprises, Inc. (NASDAQ:DXPE) or 3,175 shares. LITTLE DAVID R had sold 49,841 shares worth $2.01 million on Wednesday, March 21.

Investors sentiment decreased to 1.4 in 2017 Q4. Its down 0.17, from 1.57 in 2017Q3. It turned negative, as 16 investors sold Sangamo Therapeutics, Inc. shares while 42 reduced holdings. 35 funds opened positions while 46 raised stakes. 53.22 million shares or 2.49% more from 51.93 million shares in 2017Q3 were reported. Prudential Inc has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 117,056 shares. Spark Inv Mngmt Lc has invested 0.08% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). California State Teachers Retirement System holds 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) or 132,173 shares. Fny Managed Accounts Ltd Liability accumulated 0% or 203 shares. 4,403 were reported by Advisory Svcs Ntwk Limited Liability Com. Alliancebernstein Lp reported 0% stake. New York-based Renaissance Ltd has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Millennium Ltd Liability Corp reported 276,791 shares stake. The Illinois-based Chicago Equity Prns Ltd Liability Company has invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Keybank Natl Association Oh has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Jefferies Gru Limited Liability holds 18,005 shares. Barclays Public Limited Company owns 80,885 shares. Baldwin Brothers Ma owns 1,500 shares. Parametric Port Assocs Ltd invested in 0% or 136,789 shares. Los Angeles Cap Mgmt And Equity Rech owns 14,846 shares.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 26 analyst reports since August 8, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Friday, October 23. The rating was maintained by Jefferies with “Buy” on Friday, October 13. The firm has “Neutral” rating given on Wednesday, October 19 by Piper Jaffray. On Thursday, February 22 the stock rating was maintained by Wells Fargo with “Buy”. The firm has “Overweight” rating given on Saturday, August 8 by JP Morgan. The stock has “Neutral” rating by PiperJaffray on Wednesday, October 19. JP Morgan maintained the stock with “Buy” rating in Thursday, September 3 report. As per Tuesday, September 12, the company rating was maintained by Jefferies. The company was upgraded on Wednesday, November 15 by PiperJaffray. The rating was maintained by Jefferies with “Buy” on Wednesday, September 2.

Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.66 billion. The company's zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Since January 2, 2018, it had 0 insider purchases, and 13 sales for $2.30 million activity. Another trade for 15,000 shares valued at $345,861 was made by Herberts Curt A. III on Thursday, March 1. Ramasastry Saira had sold 9,450 shares worth $235,080. $127,812 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was sold by Yi Kathy. 11,520 shares were sold by Mento Steven J, worth $237,159 on Thursday, February 1. 5,000 shares valued at $87,065 were sold by Conner Edward R. on Friday, April 6.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>